Cathie Wood, of ARK Genomic Revolution ETF(NYSE: ARKG) explains the multi-trillion dollar opportunity in the Genomics Revolution: CAR-T, CRISPR, and DNA Sequencing
The $TRILLION Opportunity in CRISPR & DNA Sequencing Technologies
Investing Strategy
Mike Cintolo: Indicators Still Bullish. Plus: TDOC, ETSY, OKTA, CVNA
Mike Cintolo says says technical indicators still bullish. Plus: TDOC, ETSY, OKTA, CVNA Discover Tomorrow’s Winning Stocks! Thank you for subscribing. Something went wrong. Get our latest stock reports before everyone else! Actionable news, and […]
Newsmakers
CytoDyn’s (OTC: CYDY) Monotherapy Trial with Leronlimab (PRO 140) Reaches its Ultimate Goals
New data shows 525 mg dose achieves 95% response rate after the first 10 weeks of monotherapy with leronlimab Over 110 patients have reached almost one year of suppressed viral load with monotherapy on original […]
Healthcare
CytoDyn (OTC: CYDY) Submits 510(k) Pre-Submission Application to U.S. FDA for ProstaGene(TM) Prognostic Test
Dr. Richard Pestell, who leads CytoDyn’s cancer, NASH and GvHD programs, recently named to The Order of Australia, established by Queen Elizabeth II VANCOUVER, Washington, June 19, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the […]